Novo Nordisk A/S
LVMH plunge puts spot as world’s top luxury stock at risk after sales miss
Louis Vuitton store window display in Mitsukoshi department store in Tokyo, Japan, on Friday, April 4, 2025. Bloomberg | Getty Images Shares of LVMH plunged as much as 8% on Tuesday morning, at one point losing its position as world’s largest luxury firm to rival Hermès after an unexpected decline in first-quarter sales. LVMH reported […]
Read More
CNBC Daily Open: Consumers are worried over the economy. The White House insists it’ll be fine
People shop at a grocery store in Manhattan on April 01, 2025, in New York City. Spencer Platt | Getty Images A day without major tariff developments from U.S. President Donald Trump’s administration is, for markets, a day of cautious optimism (or at least what passes as “optimism” in such unusual times). There was breathing […]
Read More
Pfizer scraps daily weight loss pill after liver injury in one patient
Nikos Pekiaridis | Lightrocket | Getty Images Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in […]
Read More
Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. But the Centers […]
Read More
The biggest winners and losers in Europe as Trump announces sweeping tariffs
U.S. President Donald Trump stands, after delivering remarks on tariffs, in the Rose Garden at the White House in Washington, D.C., U.S., April 2, 2025. Leah Millis | Reuters Global markets, businesses and long-standing geopolitical relationships were thrown into disarray on Thursday, the day after U.S. President Donald Trump’s tariff policy — and Europe was not […]
Read More
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Boxes of Novo Nordisk’s weight-loss drug Wegovy in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting as the White House moves ahead with plans […]
Read More
These European stocks have the most to lose from Trump’s tariffs
European exporters to the U.S. may face significant headwinds from new tariffs President Donald Trump is expected to unveil Wednesday afternoon . While details remain scarce ahead of a Rose Garden ceremony at 4 p.m. ET, investors have been bracing themselves for broad-based levies on imports. Treasury Secretary Scott Bessent previously called out the “Dirty 15,” […]
Read More
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. Graeme Sloan | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The race to develop more convenient […]
Read More
Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four […]
Read More
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product’
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment. CEO […]
Read More